Answers are grounded in this paper and cite their sources.
Endometrial cancer (EC) is one of the most prevalent gynecological cancer subtypes affecting women, with increasing incidence partly associated with modifiable risk factors such as obesity, metabolic disturbances, and lifestyle behaviors. Standard management includes surgery, radiotherapy, chemotherapy, endocrine therapy, immunotherapy, and molecularly directed treatments selected according to disease stage, histopathological features, molecular classification, and biomarker status. Although contemporary management increasingly incorporates molecularly informed treatment and survivorship care, the role of structured lifestyle interventions in EC-specific clinical outcomes remains incompletely defined. This review explores the lifestyle factors associated with EC development and the potential role of lifestyle modifications as adjunctive strategies alongside standard therapeutic approaches in EC management. An extensive literature search across PubMed, ScienceDirect, Web of Science, and Google Scholar was conducted to identify studies examining lifestyle factors, interventions, and EC-related outcomes. Greater adherence to healthy dietary patterns and higher physical activity have been associated with lower EC incidence, while obesity is strongly associated with EC risk and adverse metabolic and clinical characteristics. Short-term preoperative weight-management interventions appear feasible and may improve selected metabolic measures. Observational evidence suggests that adiposity reduction may be associated with higher remission rates during fertility-sparing treatment. Evidence concerning alcohol consumption, psychological stress, and sleep disturbance in EC development or progression remains inconsistent or limited. Lifestyle interventions may support weight management, metabolic health, physical functioning, and quality of life. However, current evidence does not establish that they improve treatment response, prevent recurrence, or increase EC-specific survival. Lifestyle care should therefore complement, rather than replace or delay, guideline-concordant oncological treatment.
No takes yet. Share an insight, caveat, or question.
Pant et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: